Echocardiographic and hemodynamic predictors of mortality in idiopathic pulmonary fibrosis

Chest

Volumn 144, Issue 2, 2013, Pages 564-570

  Rivera Lebron, Belinda N ^a   Forfia, Paul R ^a,b   Kreider, Maryl ^a   Lee, James C ^a   Holmes, John H ^b   Kawut, Steven M ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; BODY HEIGHT; BODY WEIGHT; COHORT ANALYSIS; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HEART ATRIUM ENLARGEMENT; HEART HEMODYNAMICS; HEART INDEX; HEART LEFT VENTRICLE SIZE; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE SIZE; HEART VENTRICLE SIZE; HUMAN; LUNG ARTERY PRESSURE; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT ASSESSMENT; PATIENT REFERRAL; PREDICTION; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; SEX DIFFERENCE; UNITED STATES; UNIVERSITY HOSPITAL;

EID: 84881534544     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-2298     Document Type: Article

References (18)

1. Patel NM, Lederer DJ, Borczuk AC, Kawut SM. Pulmonary hypertension in idiopathic pulmonary fi brosis. Chest. 2007; 132 (3): 998-1006.
2. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fi brosis. Chest. 2006; 129 (3): 746-752.
3. McLaughlin VV, Presberg KW, Doyle RL, et al; American College of Chest Physicians. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004; 126 (suppl 1): 78S-92S.
4. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003; 167 (5): 735-740.
5. Fisher MR, Forfi a PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009; 179 (7): 615-621.
6. Meluzín J, Spinarová L, Bakala J, et al. Pulsed Doppler tissue imaging of the velocity of tricuspid annular systolic motion; a new, rapid, and non-invasive method of evaluating right ventricular systolic function. Eur Heart J. 2001; 22 (4): 340-348.
7. Moustapha A, Lim M, Saikia S, Kaushik V, Kang SH, Barasch E. Interrogation of the tricuspid annulus by Doppler tissue imaging in patients with chronic pulmonary hypertension: implications for the assessment of right-ventricular systolic and diastolic function. Cardiology. 2001; 95 (2): 101-104.
8. Forfi a PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006; 174 (9): 1034-1041.
9. Selimovic N, Rundqvist B, Bergh CH, et al. Assessment of pulmonary vascular resistance by Doppler echocardiography in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2007; 26 (9): 927-934.
10. Arkles JS, Opotowsky AR, Ojeda J, et al. Shape of the right ventricular Doppler envelope predicts hemodynamics and right heart function in pulmonary hypertension. Am J Respir Crit Care Med. 2011; 183 (2): 268-276.
11. Raghu G, Collard HR, Egan JJ, et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An offi cial ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fi brosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183 (6): 788-824.
12. Corte TJ, Wort SJ, Gatzoulis MA, Macdonald P, Hansell DM, Wells AU. Pulmonary vascular resistance predicts early mortality in patients with diffuse fi brotic lung disease and suspected pulmonary hypertension. Thorax. 2009; 64(10): 883-888.
13. Nathan SD, Shlobin OA, Barnett SD, et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fi brosis. Respir Med. 2008; 102 (9): 1305-1310.
14. King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fi brosis. Am J Respir Crit Care Med. 2008; 177 (1): 75-81.
15. King TE Jr, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fi brosis. Am J Respir Crit Care Med. 2011; 184 (1): 92-99.
16. Raghu GBJ, Behr J, Brown KK, et al; for the ARTEMIS-IPF Investigators. Treatment of idiopathic pulmonary fi brosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013; 158 (9): 641-649.
17. Han MK, Bach DS, Hagan P, et al; for the IPFnet Investigators. Sildenafi l preserves exercise capacity in patients with idiopathic pulmonary fi brosis and right-sided ventricular dysfunction. Chest. 2013; 143 (6): 1699-1708.
18. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW; Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafi l in advanced idiopathic pulmonary fi brosis. N Engl J Med. 2010; 363 (7): 620-628.